Fibrex initiates Phase II trial of FX06 in reperfusion injury

US biopharmaceutical company Fibrex Medical says that its Austrian subsidiary has initiated a Phase II clinical trial of its developmental drug FX06 as a treatment for reperfusion injury following treatment for heart attack. The company added that the drug is designed to address the immune response which causes damage when blood flow is restored following surgery.

The study, which will be run as a double-blind, placebo-controlled assessment, will seek to enroll 140 patients at centers in nine European countries. The trial's primary endpoint is defined as the level of myocardial salvage (tissue saved from necrosis) at five days post percutaneous coronary intervention. The company added that the drug's effects will be measured using Tc99m single-photon emission tomography and magnetic resonance imaging.